Home > > Asia And Global Direct to Consumer Genetic Testing Market- Size, Share, Growth Rate, and Forecast
The Asia Direct to Consumer Genetic Testing market was valued at $57,616.7 Million in 2023, and is projected to reach $72,381.6 Million by 2030 growing at a CAGR of 3.36% from 2024 to 2030. Clinical Chemistry segment is expected to be the highest contributor to this market, with $26,077.4 Million in 2023, and is anticipated to reach $33,008.7 by 2030, registering a CAGR of 3.47%. Human & Tumor Genetics segment is anticipated to reach $17,898.7 Million by 2030 with the highest CAGR of 3.56%. Clinical Chemistry and Human & Tumor Genetics segments collectively expected to account for about 69.7% share of the Asia Direct to Consumer Genetic Testing market in 2023, with the former constituting around 45.3% share. Human & Tumor Genetics and Clinical Chemistry segments are expected to witness significant growth rates at a CAGR of 3.56% and 3.47% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 69.7% in the overall Asia Direct to Consumer Genetic Testing market in 2023, and is anticipated to reach 70.3% by 2030. Test Type Human & Tumor Genetics Clinical Chemistry Medical Microbiology & Cytology Other Test Types Service provider Hospital-based Laboratories Stand-alone Laboratories Clinic-based Laboratories BY REGION North America U.s. Canada Mexico Europe Germany France U.k. Italy Spain Russia Rest of Europe Asia China India Japan Australia Rest of Asia Middle East & Africa Brazil South Africa GCC Rest of MENA